Efficacy News and Research

RSS

CLR01 effectively inhibits synaptotoxicity in mice with Alzheimer's

Last March, researchers at UCLA reported the development of a molecular compound called CLR01 that prevented toxic proteins associated with Parkinson's disease from binding together and killing the brain's neurons.

16 Nov 2012

New insights into how MSCs ‘traffic’ from the circulation into tissues

Mesenchymal stem cells (MSCs), are a newly emerging cellular therapy being tested in approximately 250 clinical trials worldwide to help repair damaged tissues, such as injured heart muscle following a heart attack. The problem is that when culture-expanded MSCs are injected into the circulation, they have trouble gaining access to the inflamed tissues-exactly where their help is needed.

16 Nov 2012

Meningitis vaccine declared usable without refrigeration for up to four days

"In a breakthrough for the fight against meningitis in poor countries, researchers say the WHO has ruled that a key vaccine can be transported or stored for up to four days without refrigeration," Agence France-Presse reports.

16 Nov 2012

D737 compound restores motor function and longevity in fruit flies with Alzheimer's

An efficient, high-volume technique for testing potential drug treatments for Alzheimer's disease uncovered an organic compound that restored motor function and longevity to fruit flies with the disease, according to new research that could help put the search for an effective Alzheimer's drug on a faster track.

16 Nov 2012

Tanshinones protect against sepsis: Study

Researchers at The Feinstein Institute for Medical Research have discovered that tanshinones, which come from the plant Danshen and are highly valued in Chinese traditional medicine, protect against the life-threatening condition sepsis. The findings are published in the December issue of Biochemical Pharmacology.

16 Nov 2012

Cook receives FDA approval for Zilver PTX Drug-Eluting Peripheral Stent to treat PAD

The U.S. Food and Drug Administration approved the Zilver PTX Drug-Eluting Peripheral Stent (Zilver PTX Stent), the first drug-eluting stent indicated to re-open a particular artery in the thigh (femoropopliteal artery) when narrowed or blocked as a result of peripheral artery disease (PAD).

15 Nov 2012

Peer support benefits psychoeducation for bipolar patients

Peer support for patients with bipolar disorder may help improve adherence to online psychoeducation programs, study findings suggest.

15 Nov 2012

Positive preliminary results from ImmunoPulse Phase II trial in metastatic melanoma

OncoSec Medical Inc., a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumors, announces positive preliminary results from a Phase II trial investigating the use of ImmunoPulse in metastatic melanoma patients at the 6th World Meeting of Interdisciplinary Melanoma Skin Cancer Centres & 8th EADO Congress.

15 Nov 2012

New gene delivery vehicle opens route to the heart of cells in solid tumors

There are plenty of effective anticancer agents around. The problem is that, very often, they cannot gain access to all the cells in solid tumors. A new gene delivery vehicle may provide a way of making tracks to the heart of the target.

15 Nov 2012

Adding bortezomib ‘boosts acute myeloid leukemia chemotherapy response’

Older patients with untreated acute myeloid leukemia may benefit from having bortezomib added to daunorubicin and cytarabine during induction therapy and to consolidation intermediate-dose cytarabine, the results of a US study indicate.

14 Nov 2012

Smoking cessation services delivered via mobile phones

Support for quitting smoking via text and video messages can help smokers kick the habit according to a new Cochrane systematic review. The authors of the review found that people were more likely to stay away from cigarettes over a six month period if they received motivational messages and advice to their mobile phones.

14 Nov 2012

Combination of hormones may effectively treat obesity with few side effects

Scientists at Indiana University and international collaborators have found a way to link two hormones into a single molecule, producing a more effective therapy with fewer side effects for potential use as treatment for obesity and related medical conditions.

14 Nov 2012

Hydrus stent may significantly reduce eye pressure in glaucoma patients

A tiny medical device no larger than an eyelash may significantly reduce eye pressure in glaucoma patients and allow some to stop using eye-drop medications, according to year-one clinical trial results for the device.

14 Nov 2012

EpiCept third quarter revenue increases to $0.9 million

EpiCept Corporation today reported a net loss for the three months ended September 30, 2012 of $1.1 million and a net loss for the nine months ended September 30, 2012 of $1.7 million.

14 Nov 2012

Ligand Pharmaceuticals announces data from LG-7501 preclinical studies on HCV

Ligand Pharmaceuticals Incorporated announced that data from preclinical studies evaluating LG-7501 were featured in a poster presentation today at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases in Boston.

14 Nov 2012

Study finds several osteoporosis risk factors among post-menopausal women on HRT

A preliminary study of 127 post-menopausal women on hormone replacement therapy in Portugal suggests that there are several risk factors associated with osteoporosis and bone fracture these include age, low bone mineral density, a sedentary lifestyle, coffee consumption and ovariectomy. Details are reported later this month in the International Journal of Medical Engineering and Informatics.

14 Nov 2012

Tiltan Pharma initiates enrollment in TL-118 Phase 2 trial for metastatic pancreatic cancer

Tiltan Pharma Ltd. today announced that it has enrolled the first U.S. patient, at White Plains Hospital in Westchester County N.Y., in a Phase 2 clinical trial of its anti-angiogenic product, TL-118, for the treatment of metastatic pancreatic cancer.

14 Nov 2012

Abbott releases details on phase 3 hepatitis C registrational program

Abbott today released details on its phase 3 hepatitis C registrational program following promising results from its phase 2b clinical trial, known as Aviator, presented at the Annual Meeting of the American Association for the Study of Liver Disease (AASLD) in Boston.

13 Nov 2012

Human models could be way forward for assessing analgesic efficacy

Researchers say that human experimental pain models could be used to assess the clinical efficacy of analgesics in phase I clinical studies.

13 Nov 2012

Video gaming helps coordination in children with degenerative ataxia

Whole-body controlled video gaming may help children and adolescents with degenerative ataxia to improve the physical symptoms of their condition, say researchers.

13 Nov 2012